CA2771890A1 - Condensed quinolines as protein kinase modulators - Google Patents

Condensed quinolines as protein kinase modulators Download PDF

Info

Publication number
CA2771890A1
CA2771890A1 CA2771890A CA2771890A CA2771890A1 CA 2771890 A1 CA2771890 A1 CA 2771890A1 CA 2771890 A CA2771890 A CA 2771890A CA 2771890 A CA2771890 A CA 2771890A CA 2771890 A1 CA2771890 A1 CA 2771890A1
Authority
CA
Canada
Prior art keywords
compound
optionally substituted
ring
alkyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2771890A
Other languages
English (en)
French (fr)
Inventor
Fabrice Pierre
Mustapha Haddach
Collin F. Regan
David M. Ryckman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cylene Pharmaceuticals Inc
Original Assignee
Cylene Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cylene Pharmaceuticals Inc filed Critical Cylene Pharmaceuticals Inc
Publication of CA2771890A1 publication Critical patent/CA2771890A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Peptides Or Proteins (AREA)
CA2771890A 2009-08-26 2010-08-26 Condensed quinolines as protein kinase modulators Abandoned CA2771890A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US23722709P 2009-08-26 2009-08-26
US61/237,227 2009-08-26
US28931709P 2009-12-22 2009-12-22
US61/289,317 2009-12-22
PCT/US2010/046760 WO2011025859A1 (en) 2009-08-26 2010-08-26 Condensed quinolines as protein kinase modulators

Publications (1)

Publication Number Publication Date
CA2771890A1 true CA2771890A1 (en) 2011-03-03

Family

ID=42983433

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2771890A Abandoned CA2771890A1 (en) 2009-08-26 2010-08-26 Condensed quinolines as protein kinase modulators

Country Status (13)

Country Link
US (1) US20110065698A1 (https=)
EP (1) EP2470544A1 (https=)
JP (1) JP2013503178A (https=)
KR (1) KR20120059571A (https=)
CN (1) CN102596969A (https=)
AU (1) AU2010286691A1 (https=)
BR (1) BR112012004304A2 (https=)
CA (1) CA2771890A1 (https=)
IL (1) IL218280A0 (https=)
IN (1) IN2012DN02596A (https=)
MX (1) MX2012002426A (https=)
SG (1) SG178552A1 (https=)
WO (1) WO2011025859A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6437452B2 (ja) 2013-01-14 2018-12-12 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｐｉｍキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物
RS60244B1 (sr) 2013-01-15 2020-06-30 Incyte Holdings Corp Jedinjenja tiazolkarboksamida i piridinkarboksamida korisna kao inhibitori pim kinaze
CN105658653A (zh) 2013-08-23 2016-06-08 因赛特公司 可用作pim激酶抑制剂的呋喃并-和噻吩并-吡啶甲酰胺化合物
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Ｐｉｍ激酶抑制劑之鹽
US9920032B2 (en) 2015-10-02 2018-03-20 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
BR112020000083A2 (pt) * 2017-07-03 2020-07-07 Bayer Cropscience Aktiengesellschaft novas isotiazolopiridonas substituídas, processos para sua preparação e seu uso como herbicidas e/ou reguladores de crescimento da planta
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
US11071727B2 (en) 2018-01-26 2021-07-27 Northwestern University Therapeutic targeting of proteolytic cleavage of the mixed lineage leukemia gene product (MLL1) by taspase1 using kinase inhibitors
CN117120447A (zh) * 2021-03-18 2023-11-24 薛定谔公司 环状化合物和其使用方法
WO2023126951A1 (en) * 2022-01-03 2023-07-06 Yeda Research And Development Co. Ltd. Inhibitors of autophagy-related protein-protein interactions
GB202213166D0 (en) * 2022-09-08 2022-10-26 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
GB202213163D0 (en) * 2022-09-08 2022-10-26 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559235A (en) 1991-10-29 1996-09-24 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
US5342947A (en) 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5491237A (en) 1994-05-03 1996-02-13 Glaxo Wellcome Inc. Intermediates in pharmaceutical camptothecin preparation
US5624677A (en) 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
EP1218358B1 (en) 1999-09-23 2006-09-13 AstraZeneca AB Therapeutic quinazoline compounds
TW200526626A (en) 2003-09-13 2005-08-16 Astrazeneca Ab Chemical compounds
NZ560969A (en) 2005-02-17 2010-08-27 Albany Molecular Res Inc Benzoxazole carboxamides for treating chemotherapy-induced vomiting and irritable bowel syndrome
US7956064B2 (en) * 2006-09-01 2011-06-07 Cylene Pharmaceuticals, Inc. Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators
AU2009219154A1 (en) * 2008-02-29 2009-09-03 Cylene Pharmaceuticals, Inc. Protein kinase modulators
TW201024297A (en) * 2008-09-10 2010-07-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease
TW201204727A (en) * 2010-03-10 2012-02-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease

Also Published As

Publication number Publication date
EP2470544A1 (en) 2012-07-04
US20110065698A1 (en) 2011-03-17
CN102596969A (zh) 2012-07-18
AU2010286691A1 (en) 2012-04-19
MX2012002426A (es) 2012-06-27
KR20120059571A (ko) 2012-06-08
JP2013503178A (ja) 2013-01-31
IL218280A0 (en) 2012-04-30
SG178552A1 (en) 2012-03-29
BR112012004304A2 (pt) 2016-03-15
WO2011025859A1 (en) 2011-03-03
IN2012DN02596A (https=) 2015-08-28

Similar Documents

Publication Publication Date Title
CA2771890A1 (en) Condensed quinolines as protein kinase modulators
US8367681B2 (en) Pyrazolopyrimidines and related heterocycles as kinase inhibitors
JP2022525010A (ja) 疾患の治療のための化合物、組成物、及び方法
JP6204568B2 (ja) タンパク質キナーゼ阻害剤としての縮合複素環化合物
DK2448938T5 (en) Pyrimidinones AS PI3K inhibitors
US20100298302A1 (en) Novel protein kinase modulators
JP2011521968A (ja) プリンｐｉ３ｋ阻害剤化合物および使用方法
ES2994614T3 (en) Nitrogen-containing fused heterocyclic compound, as well as preparation method, intermediate, composition and application thereof
CN102625803A (zh) 药学上有用的杂环-取代的内酰胺
BR112020011746A2 (pt) compostos heterocíclicos bicíclicos substituídos atuando como inibidores de prmt5
AU2006284751A1 (en) Raf inhibitor compounds and methods of use thereof
TW201014864A (en) Thienopyrimidines for pharmaceutical compositions
CA2774148A1 (en) Tricyclic compounds and pharmaceutical uses thereof
AU2010236162A1 (en) Method of treating disorders associated with protein kinase CK2 activity
CA3188446A1 (en) Eif4e-inhibiting 4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine compounds
JP2016526545A (ja) スルホキシイミン置換キナゾリンならびにｍｎｋ１および／またはｍｎｋ２キナーゼ阻害薬としてのその使用
CA2873971A1 (en) Substituted pyrrolopyrimidines
TW201625629A (zh) 新穎吡咯并嘧啶化合物或其鹽，及含有其之醫藥組成物，特別是基於ｎａｅ抑制作用的腫瘤等之預防劑及／或治療劑
KR20140139023A (ko) 암을 치료하기 위한 6-(4-(1-아미노-3-하이드록시사이클로부틸)페닐)-5-페닐(퓨로, 싸이에노 또는 피롤로)[2,3-d]피리미딘-4-온 유도체
RU2669696C2 (ru) КОНФОРМАЦИОННО ОГРАНИЧЕННЫЕ ИНГИБИТОРЫ PI3K И mTOR
Federico et al. [1, 2, 4] Triazolo [1, 5‐c] pyrimidines as Tools to Investigate A3 Adenosine Receptors in Cancer Cell Lines
SA120410777B1 (ar) مشتقات مضادة للسرطان 1،3-dioxane-4،6-dione وطريقة التركيب التجميعي لها
BR112017021114B1 (pt) Compostos heterocíclicos como inibidores de lsd1, seu uso, composição farmacêutica que os compreende e método para inibir a demetilase lisina-específica 1 (lsd1) in vitro
HK1201266B (en) Fused tetra or penta-cyclic pyridophthalazinones as parp inhibitors

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20140826